Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ataluren in nonsense-mutation-mediated DMD and BMD
NCT00592553Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Feb 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of ataluren in Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), sponsored by PTC Therapeutics, Inc. Started Feb 2008; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT00592553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592553.